- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06325020
Objective Risk Assessment in Patients With Possible Anginal Chest Pain Using Leading Technology (ORACLE)
ORACLE: Objective Risk Assessment in Patients With Possible Anginal Chest Pain Using Leading Technology
The ORACLE study is an observational cohort study designed to explore the feasibility of providing an assessment of chest pain for patients with suspected angina within one working day of referral to specialist services.
The primary objective is to determine the feasibility of delivering an objective assessment of risk for participants who have been referred by their primary care provider to the rapid access chest pain clinic with possible angina in a community setting using point of care and patient facing technologies within one working day of referral.
Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.
Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured by point of care high sensitivity cardiac troponin assays as well as a core lab assay.
The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent onset of angina is a clinical manifestation of unstable or progressive coronary artery disease and is a common presentation within primary care. Evaluation can be challenging as access to objective measures of risk and diagnostic testing are limited in this setting. Due to capacity, not all patients referred to the rapid access chest pain clinic can be reviewed within this clinic.
Patients are often high risk with suspected obstructive coronary artery disease, and the aim should be for review, assessment and if required, initiation of therapy, without undue delay.
This study has been designed to explore the feasibility of delivering a virtual chest pain assessment for patients with new onset chest pain. It is an observational cohort study, that uses a combination of digital tools to capture relevant patient information and clinical history, point-of-care high-sensitivity cardiac troponin testing and electrocardiography.
This pathway will aim to provide an objective assessment of risk on the next working day following primary care contact to all patients referred to the rapid access chest pain clinic.
On completion of this assessment patients will be stratified to low, intermediate or high risk groups based on their symptoms, risk factors, point of care troponin value (ng/l) and ECG. The results will not be made available to the clinical team unless the patients was at risk of harm (acute coronary syndrome or arrhythmia). Patients will return to receive routine clinical care.
The investigators plan to recruit 300 participants or for six months, whatever arises first. Participants can only be recruited once during the study period.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Michael McDermott, MBChB
- Phone Number: 07966024516
- Email: michael.mcdermott@ed.ac.uk
Study Contact Backup
- Name: Nicholas L Mills, MD
- Email: nick.mills@ed.ac.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- >30 years of age
- Referral to the rapid access chest pain clinic with possible new onset or worsening angina
Exclusion Criteria:
- Inability to give informed consent.
- Previous recruitment to the study.
- Acute coronary syndrome within 3 months.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with possible angina
Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms. Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured. The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events. |
Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms. Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured. The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants in whom a chest pain risk assessment is complete within one working day of referral.
Time Frame: This is the time from referral to rapid access chest pain clinic through to completion of their visit, anticipated to be between 1 and 3 days.
|
The proportion of participants who have been referred by their primary care provider to the rapid access chest pain clinic with possible angina in whom a complete risk assessment is delivered in a community setting using point of care and patient facing technologies within one working day of referral.
|
This is the time from referral to rapid access chest pain clinic through to completion of their visit, anticipated to be between 1 and 3 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who can have their risk assessment completed in one, two or three or more working days from referral to service until completion of risk assessment.
Time Frame: This is the time from referral to rapid access chest pain clinic through to completion of their visit, anticipated to be between 1 and 3 days.
|
The proportion of participants who have been referred by their primary care provider to the rapid access chest pain clinic with possible angina in whom a complete risk assessment is delivered in a community setting using point of care and patient facing technologies within one, two or three or more working days of referral.
|
This is the time from referral to rapid access chest pain clinic through to completion of their visit, anticipated to be between 1 and 3 days.
|
Proportion of valid and interpretable point-of-care troponin tests
Time Frame: This will be completed during the patients study visit, anticipated to last 1 hour
|
This will be the proportion of patients in whom a valid high sensitivity cardiac troponin result can be obtained from undertaking the point of care assay.
|
This will be completed during the patients study visit, anticipated to last 1 hour
|
Proportion of personal electrocardiograms that are interpretable
Time Frame: This will be completed during the patients study visit, anticipated to last 1 hour
|
This will be the proportion of patients in whom an interpretable personal ECG has been performed
|
This will be completed during the patients study visit, anticipated to last 1 hour
|
Proportion of participants stratified as low, intermediate, or high risk using objective risk stratification.
Time Frame: This will be completed during the patients study visit, anticipated to last 1 hour
|
This will be the proportion of patients who are stratified into low, intermediate or high risk groups on completion of their risk assessment.
|
This will be completed during the patients study visit, anticipated to last 1 hour
|
Proportion of participants with and without a clinical diagnosis of angina stratified as low, intermediate, or high risk and according to triage status.
Time Frame: This will be obtained at 3 months following completion of the patient's assessment.
|
This will be the proportion of patients who do and do not receive a clinical diagnosis of angina and this will be stratified by triage status
|
This will be obtained at 3 months following completion of the patient's assessment.
|
Proportion of participants with unscheduled Emergency Department attendance(s) at 3 months stratified as low, intermediate, or high risk and according to triage status.
Time Frame: This will be obtained at 3 months following completion of the patient's assessment.
|
This will be the proportion of patients who present acutely to the emergency department in the 3 months following assessment.
This will be stratified by risk stratification and their clinical triage status.
|
This will be obtained at 3 months following completion of the patient's assessment.
|
Proportion of participants with cardiac death or non-fatal myocardial infarction at 3 months stratified as low, intermediate, or high risk and according to triage.
Time Frame: This will be obtained at 3 months following completion of the patient's assessment.
|
This will be the proportion of patients who have cardiac death or fatal myocardial infarction in the 3 months following assessment.
This will be stratified by risk stratification and their clinical triage status.
|
This will be obtained at 3 months following completion of the patient's assessment.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants reclassified as low, intermediate, or high risk using standard laboratory assays compared to point-of-care high-sensitivity cardiac troponin assay.
Time Frame: This will be completed during the patients study visit, anticipated to last 1 hour
|
Patients will have a point of care troponin and a core laboratory high sensitivity troponin.
The proportion of patients who are re-classified by the current laboratory clinical standard will be recorded
|
This will be completed during the patients study visit, anticipated to last 1 hour
|
Proportion of participants reclassified as low, intermediate, or high risk using standard 12-lead compared to personal 12-lead electrocardiography
Time Frame: This will be completed during the patients study visit, anticipated to last 1 hour
|
Patients will have a standard 12 lead and personal ECG.
The proportion of patients who are re-classified by the current clinical standard 12 lead ECG will be recorded.
|
This will be completed during the patients study visit, anticipated to last 1 hour
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael McDermott, MBCHB, University of Edinburgh
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 337367
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on The assessment of patients with possible angina using the ORACLE pathway
-
Montreal Heart InstituteCompleted
-
Assistance Publique Hopitaux De MarseilleUnknownInfective Endocarditis (IE)France
-
University Hospital Inselspital, BerneUniversity of Colorado, Denver; Mayo Clinic; Northwestern University; University... and other collaboratorsUnknownDeglutition Disorders | Esophageal Diseases | EosinophiliaUnited States, Canada, Switzerland, United Kingdom
-
Poitiers University HospitalCompletedPostnatal DepressionFrance
-
Universidad de SonoraCompletedBlood Pressure | Dialysis | Chronic Renal Failure | Dry WeightMexico
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Centre hospitalier de l'Université de Montréal...Completed
-
Fernandez ZamoraRecruitingColorectal Cancer | Wound Infection | Incisional HerniaSpain
-
Bahçeşehir UniversityCompletedDental Caries | Caries; DentinTurkey
-
Ankara City Hospital BilkentCompletedChildren, Only | Tracheal Intubation Morbidity | Cuff | Airway EdemaTurkey